Penserra Capital Management LLC Crispr Therapeutics Ag Transaction History

Penserra Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$45.39 - $59.0 $46,433 - $60,357	1,023 Added 26.5%	4,884 $221,000
Q2 2023 Aug 11, 2023	SELL	$43.47 - $67.77 $57,336 - $89,388	-1,319 Reduced 25.46%	3,861 $216,000
Q1 2023 Apr 24, 2023	SELL	$41.0 - $56.12 $4,100 - $5,612	-100 Reduced 1.89%	5,180 $234,000
Q4 2022 Feb 13, 2023	SELL	$39.19 - $65.67 $110,202 - $184,664	-2,812 Reduced 34.75%	5,280 $214,000
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $391,773 - $537,197	6,412 Added 381.67%	8,092 $528,000
Q2 2022 Aug 15, 2022	SELL	$43.23 - $73.83 $21,096 - $36,029	-488 Reduced 22.51%	1,680 $102,000
Q1 2022 May 13, 2022	BUY	$53.19 - $79.24 $115,315 - $171,792	2,168 New	2,168 $136,000
Q4 2020 Feb 12, 2021	SELL	$79.67 - $173.23 $47,642 - $103,591	-598 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$78.5 - $100.64 $46,943 - $60,182	598 New	598 $50,000

489

57.9M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.1B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.